Zomacton Shortage: What Providers and Prescribers Need to Know in 2026

For providers managing patients on Zomacton (somatropin, Ferring Pharmaceuticals), understanding the current landscape of specialty pharmacy access, insurance prior authorization requirements, and formulary positioning is essential for ensuring continuity of care. This guide provides a clinical and practical overview of Zomacton's availability and access challenges in 2026.

Current Shortage Status

As of 2026, Zomacton is not listed on the FDA Drug Shortage Database, and Ferring Pharmaceuticals has not issued a public supply disruption notice. The broader somatropin market in the United States remains generally stable, with other brands including Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Eli Lilly), Omnitrope (Sandoz), and Saizen (Merck) all available without active shortage designations.

Despite the absence of a formal shortage, many patients experience significant access barriers related to specialty pharmacy distribution, prior authorization requirements, and insurance formulary positioning. These barriers can present to providers as apparent supply issues when they are in fact access and administrative challenges.

Why Patients and Practices Encounter Zomacton Access Difficulties

Several structural factors contribute to Zomacton access challenges:

• Specialty-only distribution: Zomacton is dispensed exclusively through specialty pharmacies equipped for cold-chain biologics. Standard retail pharmacies will not stock or fill this prescription. Sending prescriptions to retail locations is one of the most common avoidable delays.
• Universal prior authorization requirements: Growth hormone therapy requires prior authorization on virtually all commercial and government insurance plans. Criteria typically require documented GHD (stimulation testing results), condition-specific documentation (e.g., karyotype for Turner syndrome), and often a prescriber attestation that dose doesn't exceed labeled recommendations.
• Step therapy and formulary positioning: Many commercial plans position Zomacton as non-preferred, requiring step therapy through a preferred product (often Norditropin or Omnitrope) before covering Zomacton. Medical necessity exceptions are available but require additional documentation.
• Specialty pharmacy network restrictions: Certain plans restrict specialty pharmacy dispensing to one or two contracted pharmacies, which may not be local to the patient. Mail-order delivery through the plan's specialty pharmacy is often the only covered option.

Clinical Profile: Indications and Dosing Review

Zomacton (somatropin) is FDA-approved for:

• Pediatric growth failure due to inadequate GH secretion (GHD): 0.18–0.3 mg/kg/week divided into daily or 6x/week doses
• Turner syndrome: Up to 0.375 mg/kg/week
• Idiopathic short stature (ISS, HSDS ≤ -2.25): Up to 0.37 mg/kg/week
• SHOX deficiency and SGA (no catch-up growth by ages 2-4): Per FDA-labeled dosing
• Adult GHD: Start 0.15–0.3 mg/day; titrate by 0.1–0.2 mg/day every 1-2 months based on IGF-1 and clinical response

Zomacton is available as a lyophilized powder in 5 mg and 10 mg single-patient-use vials, administered by subcutaneous injection. The 5 mg formulation is co-packaged with bacteriostatic 0.9% sodium chloride (0.9% benzyl alcohol); the 10 mg formulation uses bacteriostatic water for injection (0.33% metacresol). Use normal saline for reconstitution when administering the 5 mg to neonates or infants due to benzyl alcohol toxicity risk.

Key Monitoring Parameters During Zomacton Therapy

Routine monitoring during Zomacton therapy should include:

• IGF-1 levels (to guide dose titration in adults and monitor for safety in pediatric patients)
• Thyroid function (hypothyroidism may emerge or worsen on somatropin)
• Glucose and HbA1c (somatropin can decrease insulin sensitivity; monitor for new-onset T2DM)
• Fundoscopic examination prior to initiating treatment and periodically thereafter (intracranial hypertension risk, usually within 8 weeks of initiation)
• In pediatric patients: height velocity, bone age, and assessment for slipped capital femoral epiphysis (hip/knee pain or limp) and scoliosis progression

38,004+ patients found their medications in stock

38K+

Find Zomacton In Stock Today →

When to Consider Switching to an Alternative Somatropin

Consider initiating a brand switch when:

• Zomacton is non-preferred on the patient's current formulary and a medical exception is unlikely to be approved
• Patients are experiencing ongoing specialty pharmacy access issues without a formulary pathway to resolve them
• Patient or caregiver requests a different delivery system (e.g., prefilled pen vs. reconstituted vial)
• Once-weekly dosing would improve adherence (Skytrofa for pediatric patients ≥1 year, ≥11.5 kg; Sogroya for adults)

Ferring Support Resources for Your Practice

Ferring Pharmaceuticals provides dedicated support for prescribers through the ZoGo support program. This includes PA submission assistance, preferred specialty pharmacy routing, and patient financial assistance programs. Prescribers can access these resources at zomactonhcp.com or by calling 1-844-567-9501.

Skip the calls, skip the stress.

Find Zomacton In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How medfinder Supports Your Patients

For patients who are having difficulty locating Zomacton at a pharmacy near them, medfinder is a service that calls pharmacies on the patient's behalf to check which ones can fill their prescription — and texts them the results. Recommending medfinder to patients experiencing access difficulties can reduce the burden on your office staff and accelerate prescription fulfillment.

See also: How to Help Your Patients Find Zomacton In Stock: A Provider's Guide.